### **Overview** Brooks Laboratories Limited (BLL), incorporated on January 23, 2002, is an established Indian pharmaceutical company specializing in the manufacturing of critical care medicines, particularly sterile injectables. With over two decades of experience, the company has built a strong footprint in both domestic and international markets. It operates two state-of-the-art manufacturing facilities — one in **Baddi, Himachal Pradesh**, and another in **Vadodara, Gujarat**, the latter being part of a strategic joint venture and holding USFDA approval. The company is led by experienced promoters **Atul Ranchal** and **Rajesh Mahajan**, each with nearly 20 years of industry expertise, supported by a seasoned management team bringing over 20 years of collective experience. --- ### **Core Business Segments & Operations** #### **1. Critical Care Division (CCD) – Domestic Focus** - Launched in 2018, CCD is a key pillar of BLL’s domestic growth strategy. - Distributes high-quality injectable pharmaceuticals across India via a **pan-India network** supported by approximately **140 medical sales professionals** (up from 100 in 2023). - Serves hospitals and healthcare institutions with a focus on: - Specialty critical care medicines - Broad-spectrum antibiotics for multi-drug resistant infections - Beta-lactam and carbapenem-based products - Pain management & nutritional support - Ophthalmic range: eye drops for infections, allergies, dry eyes, inflammation, and surgical recovery - Since 2019, has launched **~70 brands** in the branded generics segment, achieving a **CAGR of 50%** in sales within this division. #### **2. Manufacturing Capabilities** - Wide range of dosage forms manufactured: - Liquid & dry powder injections (including beta-lactam and carbapenems) - Ampoules, vials, tablets, dry syrups, oral suspensions - Oncology and hormonal injectables - Eye/ear drops - Portfolio includes **95+ products**, with **over 50 market authorizations** across non-regulated and semi-regulated markets. - Facilities accredited by regulatory bodies in **Yemen, Afghanistan, Cambodia, Ivory Coast, and Nigeria**. - Operational excellence enhanced through automation and compliance upgrades to meet higher regulatory standards. #### **3. Contract Development & Manufacturing (CDMO & Third-Party)** - A significant contributor to consolidated revenues. - Offers **Contract Research and Manufacturing Services (CRAMS)** and CDMO solutions. - Supports third-party manufacturing across multiple dosage forms for domestic and international clients. --- ### **International Strategy & Expansion** #### **Target Markets** - Focus on **semi-regulated and SPOT tender-driven markets**, particularly: - **Latin America (LATAM):** Bolivia, Ecuador, Dominican Republic, El Salvador, etc. - **Africa:** Nigeria, DR Congo, Sudan, Uganda, Mauritius, etc. - **Middle East & Other Regions:** Afghanistan, Yemen, Lebanon, Kosovo, Georgia, Myanmar - Active SPOT tender participation in **Uganda, Lebanon, and Sudan**; expanding product registrations in these regions. #### **Growth Drivers** - **Double-digit profitable growth** targeted through: - Expansion of product registrations in priority countries - Development of a **differentiated beta-lactam-focused portfolio** - Launch of new products such as **Heparin Injection, Propofol Inj, and Meglumine Antimoniate Inj** - Strengthening partnerships with domestic exporters for merchant trade #### **Regulatory Advancements** - Vadodara facility (JV entity) received: - **USFDA approval** for Meropenem injection (2022) - Regulatory clearance in **all 30 EU countries**, including the UK - Plans to expand regulatory filings in FWA, Myanmar, Dominican Republic, and other semi-regulated geographies. --- ### **Joint Ventures & Strategic Partnerships** #### **Brooks Steriscience Limited (BSL) – Vadodara JV** - Formed in 2020 with **Steriscience Specialties Private Limited**, a partner with strong regulatory and commercial expertise in **regulated markets (US, Europe, Canada, Australia)**. - **Ownership**: Initially, Brooks held 49%, Steriscience 51% (post-investment). - Vadodara facility serves as **exclusive manufacturer** for the front-end commercialization entity targeting regulated markets. - Steriscience committed investments up to **$100 million (front-end)** and **₹8,400 million (~$104M)** for API and lyophilization line development. - Enabled **backward integration** with in-house **Carbapenem API facility**, reducing reliance on foreign suppliers. #### **Commercial Milestones** - **First ANDA approval from USFDA** (Meropenem injection) in 2022; launched in US market by Q4 2022. - Additional ANDAs expected to contribute to near-term revenue growth. #### **Joint Venture Objectives** - Accelerate global expansion into regulated markets - Enhance manufacturing quality and credibility - Achieve **supply chain resilience** and cost efficiency - Position as a global player in the **$2+ billion penem antibiotics market** --- ### **Innovation, R&D & Future Growth** - R&D team focused on **stabilizing new molecules** in niche therapeutic areas. - Invested in **automation, facility expansion**, and regulatory readiness. - Equity infusion planned via **preferential issue** (Dec 2024) to strengthen balance sheet and support JV and associate company growth. --- ### **Strategic Transformation (2020–2025)** | Initiative | Status / Achievement | |----------|------------------------| | **Shift from B2B to B2C** | Launched in 2018; now in 6+ Indian states with pan-India ambitions; target: **50% of sales via internal marketing team** | | **Expansion beyond institutional sales** | Reducing dependency on uncertain payments; building brand equity | | **Global positioning** | Emphasis on cost-effective, faster delivery of therapies to underserved and semi-regulated markets | | **CDMO Synergies** | Proposed amalgamation of Steriscience SG and BSL operations into **OneSource (Stelis Biopharma)** to create a unified biologics and sterile injectables CDMO platform | --- ### **OneSource Amalgamation (Planned Strategic Move – Sep 2025)** - OneSource (formerly Stelis Biopharma Ltd) is a **publicly listed CDMO** for biologics in injectable format. - **Proposed amalgamation** aims to consolidate: - Steriscience SG’s sterile injectables operations - BSL’s Carbapenem manufacturing arm - Expected outcomes: - Broadened product and service offerings - Unified talent pool and customer base - Operational synergies and improved management coordination - Enhanced global expansion in CDMO space --- ### **Steriscience SG Structure (Sep 2025 Update)** - Singapore-based holding entity with IP-led B2B and trading operations. - Owns indirect stake in **manufacturing facility in Poland** via Dutch subsidiary **Steriscience B.V.** and Polish entity **Steriscience Sp. z.o.o.** - Planning to transfer trading and IP operations to newly formed **Steriscience Pharma Pte Ltd** (wholly owned subsidiary). - Post-transfer, Steriscience SG will function as a **pure holding company**. --- ### **Key Strengths** ✅ Dual manufacturing facilities, including **USFDA-approved** site ✅ Backward integration via **in-house Carbapenem API facility** ✅ Strong focus on **critical care and anti-infectives** in high-demand segments ✅ Strategic joint venture with deep global reach and funding ✅ Robust CDMO and third-party manufacturing arm ✅ Expanding domestic marketing with growing B2C presence ✅ Global ambitions via semi-regulated and regulated market penetration ---